What is the latest VALIANTLAB stock price?
The latest stored price for VALIANTLAB is Rs 64.01 as of 2026-07-20.
VALIANT LABORATORIES LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available VALIANTLAB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
The latest stored price for VALIANTLAB is Rs 64.01 as of 2026-07-20.
VALIANTLAB is below 50DMA, below 200DMA. The latest 50DMA is 70.60 and the latest 200DMA is 69.28.
VALIANTLAB has PE -105.99, ROE -1.20%, and ROCE +0.75% in Gimli's latest available snapshot.
VALIANTLAB has returned -5.73% over 1 month, -3.67% over 3 months, and -37.73% over 12 months in the latest stored data.
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 91.98 cr | 4.98 cr | 1.76 cr | 0.32 |
| 2025-12-31 | 52.46 cr | -0.26 cr | -7.06 cr | -1.30 |
| 2025-09-30 | 46.20 cr | 0.94 cr | 0.20 cr | 0.04 |
| 2025-06-30 | 46.82 cr | 3.05 cr | 1.82 cr | 0.39 |
| 2025-03-31 | 57.79 cr | 1.51 cr | 0.70 cr | 0.16 |
| 2024-12-31 | 35.23 cr | 2.20 cr | n/a | nan |
| 2024-09-30 | 21.48 cr | -3.38 cr | n/a | -1.09 |
| 2024-06-30 | 18.88 cr | 0.43 cr | -0.51 cr | -0.11 |
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 237.47 cr | 8.71 cr | -3.27 cr | nan |
| 2025-03-31 | 133.38 cr | 0.76 cr | -2.20 cr | -0.51 |
| 2024-03-31 | 182.06 cr | 1.27 cr | 0.32 cr | 0.12 |
| 2023-03-31 | 333.91 cr | 39.95 cr | 29.00 cr | 6.19 |
| 2022-03-31 | 291.52 cr | 44.27 cr | n/a | 5.87 |
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 463.98 cr | 3.53 cr | 46.21 cr | 310.89 cr |
| 2025-03-31 | 400.86 cr | 4.92 cr | 121.69 cr | 234.31 cr |
| 2024-03-31 | 342.69 cr | 11.72 cr | 76.71 cr | 236.86 cr |
| 2023-03-31 | 212.97 cr | 1.26 cr | 60.22 cr | 100.49 cr |
| 2022-03-31 | 181.81 cr | 0.13 cr | 61.13 cr | 71.46 cr |
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | -10.43 cr | -44.63 cr | n/a |
| 2025-03-31 | 1.31 cr | -112.54 cr | n/a |
| 2024-03-31 | 1.89 cr | -43.98 cr | n/a |
| 2023-03-31 | 56.05 cr | 18.37 cr | n/a |
| 2022-03-31 | 2.25 cr | -4.62 cr | n/a |
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +74.94% | +0.20% | +0.00% | +0.00% | +24.86% | +0.00% |
| 2025-12-31 | +74.94% | +0.01% | +0.00% | +0.00% | +25.05% | +0.00% |
| 2025-09-30 | +74.94% | +0.02% | +0.00% | +0.00% | +25.04% | +0.00% |
| 2025-08-11 | +74.94% | +0.52% | +0.00% | +0.00% | +24.54% | +0.00% |
| 2025-06-30 | +74.94% | +0.63% | +0.46% | +0.00% | +23.97% | +0.00% |
| 2025-03-31 | +74.94% | +0.64% | +0.00% | +0.00% | +24.42% | +0.00% |
| 2024-12-31 | +74.94% | +0.00% | +0.00% | +0.00% | +25.06% | +0.00% |
| 2024-09-30 | +74.94% | +0.00% | +0.00% | +0.00% | +25.06% | +0.00% |
| 2024-06-30 | +74.94% | +1.89% | +0.00% | +0.00% | +23.17% | +0.00% |
| 2024-03-31 | +74.94% | +3.48% | +0.03% | +0.00% | +21.55% | +0.00% |
| 2023-12-31 | +74.94% | +7.08% | +0.47% | +0.00% | +17.51% | +0.00% |
| 2023-10-04 | +74.94% | +8.64% | +3.89% | +0.00% | +12.53% | +0.00% |
| 2023-09-30 | +74.94% | +8.64% | +3.89% | +0.00% | +12.53% | n/a |
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Data snapshot: 2026-07-20. Not investment advice.